Bibert, StephanieWojtowicz, AgnieszkaTaffe, PatrickTarr, Philip E.Bernasconi, EnosFurrer, HansjakobGunthard, Huldrych F.Hoffmann, MatthiasKaiser, LaurentOsthoff, MichaelFellay, JacquesCavassini, MatthiasBochud, Pierre-Yves2019-01-042019-01-042019-01-042018-11-2810.1097/QAD.0000000000002004https://infoscience.epfl.ch/handle/20.500.14299/153345WOS:000453912600011Background: Kaposi's sarcoma, the most common AIDS-related cancer, represents a major public concern in resource-limited countries. Single nucleotide polymorphisms within the Interferon lambda 3/4 region (IFNL3/4) determine the expression, function of IFNL4, and influence the clinical course of an increasing number of viral infections.Objectives: To analyze whether IFNL3/4 variants are associated with susceptibility to AIDS-related Kaposi's sarcoma among MSM enrolled in the Swiss HIV Cohort Study (SHCS).Methods: The risk of developing Kaposi's sarcoma according to the carriage of IFNL3/4 SNPs rs8099917 and rs12980275 and their haplotypic combinations was assessed by using cumulative incidence curves and Cox regression models, accounting for relevant covariables.Results: Kaposi's sarcoma was diagnosed in 221 of 2558 MSM Caucasian SHCS participants. Both rs12980275 and rs8099917 were associated with an increased risk of Kaposi's sarcoma (cumulative incidence 15 versus 10%, P=0.01 and 16 versus 10%, P=0.009, respectively). Diplotypes predicted to produce the active P70 form (cumulative incidence 16 versus 10%, P=0.01) but not the less active S70 (cumulative incidence 11 versus 10%, P=0.7) form of IFNL4 were associated with an increased risk of Kaposi's sarcoma, compared with those predicted not to produce IFNL4. The associations remained significant in a multivariate Cox regression model after adjustment for age at infection, combination anti retrovi ral therapy, median CD4(+) T-cel I count nadir and CD4(+) slopes (hazard ratio 1.42, 95% confidence interval 1.06-1.89, P=0.02 for IFLN P70 versus no IFNL4).Conclusion: This study reports for the first time an association between IFNL3/4 polymorphisms and susceptibility to AIDS-related Kaposi's sarcoma. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.ImmunologyInfectious DiseasesVirologyImmunologyInfectious DiseasesVirologyaidshivinterferon lambda 3immunogeneticskaposi's sarcomapolymorphismchronic hepatitis-cpotent antiretroviral therapyifn-lambdapromoter polymorphismsusceptibility geneantitumor-activityribavirin therapyhcv clearance1 expressionin-vitrotext::journal::journal article::research article